Dr Reddy's Laboratories Limited announced today that it has entered into a licensing agreement with Hyderabd-based Hetero Drugs Limited to distribute and market chronic hepatitis C medicine Sofosbuvir 400 mg under the brand name Resof in India.
Hetero was among several other generic drug companies, including Natco Pharma, which were granted a non-exclusive license by Gilead Sciences to manufacture and market its patented medicine Sofosbuvir in 91 countries including India.
Hetero and others had also received the approval from the Drug Controller General of India (DCGI) to manufacture and sell the medicine in India.
Dr Reddy's did not elaborate much on the said agreement though the licensing pact with Hetero would mean it would distribute the drug manufactured by Hetero. The latter has tied up with various license holders to distribute the medicine in India.
"The launch of Resof is in line with Dr Reddy's philosophy of innovative medicine at an affordable price and will provide significant relief to patients, resulting in potential cure and a higher barrier to resistance at an affordable price for those living with hepatitis C," Dr Reddy's co-chairman and CEO, G V Prasad said.
While Dr Reddy's has not revealed the price at which it was going to sell the medicine in the Indian market, Hetero announced a price of Rs 19,900 for a bottle of 28 tablets earlier this month.
No comments:
Post a Comment